Abstracts tagged "Hepatitis"

Abstract Number: 1336 • 2013 ACR/ARHP Annual Meeting
The Safety and Feasibility Of a Treat-To-Target Strategy Aimed At Achieving a Simplified Disease Activity Index Of ¡Ü3.3 While Administering Entecavir In Rheumatoid Arthritis Complicated By Hepatitis B Virus
Yukitomo Urata¹, Yoshihide Nakamura^2,3 and Ken-ichi Furukawa⁴, ¹Seihoku Central Hospital, United Municipalities of Tsugaru, Gosyogawara, Japan, ²Hirosaki University Graduate School of Medicine, Hirosaki, Japan, ³Orthopaedic Surgery, Seihoku Central Hospital, United Municipalities of Tsugaru, Gosyogawara, Japan, ⁴Pharmacology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
Background/Purpose: To elucidate the safety and feasibility of a treat-to-target (T2T) strategy aimed at achieving a simplified disease activity index (SDAI) of ≤3.3 while administering…
Abstract Number: 572 • 2013 ACR/ARHP Annual Meeting
Immunization With Hepatitis B Vaccine Accelerates SLE-Like Disease In An Animal Model
Nancy Agmon-Levin¹, María Teresa Arango², Shaye Kivity³, Aviva Katzav⁴, Boris Gilburd⁵, Miri Blank^6,7, Juan-Manuel Anaya⁸, Gisele Zandman-Goddard⁹, Joab Chapman¹⁰ and Yehuda Shoenfeld¹¹, ¹The Zabludowicz Center for Autoimmune Diseases, Tel-Hashomer, Israel, ²Doctoral Program in Biomedical Sciences Universidad del Rosario, Bogota, Colombia;Center for Autimmune Diseases Research – CREA, Universidad del Rosario,, Bogota, Colombia, ³Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, affliated to Sackler Faculty of Medicine, Tel-Aviv University Israel, Tel-Aviv, Israel, ⁴Department of. Neurology and Sagol Neuroscience Center, Sheba Medical Center,Tel-Hashomer, Ramat Gan, Israel, ⁵The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel, ⁶Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, affiliated to Sackler Medical School, Tel Aviv University, Ramat Gan, Israel, ⁷Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, affiliated to Sackler Faculty of Medicine,Tel Aviv University, Tel-Aviv, Tel-Aviv, Israel, ⁸School of Medicine and Health Sciences, Universidad del Rosario. Center for Autoimmune Diseases Research (CREA), Bogotá, Colombia, ⁹Internal Medicine C, Wolfson Medical Center;Sackler Faculty of Medicine, Tel-Aviv University, Holon, Israel, ¹⁰Department of. Neurology and Sagol Neuroscience Center, Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel, ¹¹The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Ramat Gan, Israel
Background/Purpose: Hepatitis-B vaccine (HBVv) was proven to be successful and cost effective in preventing HBV infection and associated liver disease. However, in recent years concerns…
Abstract Number: 486 • 2013 ACR/ARHP Annual Meeting
Safety Of Biologic Therapy In Veterans With Rheumatoid Arthritis and Chronic Hepatitis B Infection
Jeffrey R. Curtis¹, Mary J. Burton², Shuo Yang³, Lang Chen⁴, Ted R. Mikuls⁵, Kevin L. Winthrop⁶ and John Baddley⁷, ¹University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL, ²VA Hospital, Jackson, MS, ³Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁶Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ⁷Medicine, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Among patients with rheumatoid arthritis and hepatitis B infection, the impact of biologic therapy on hepatotoxicity has received limited study. Methods: Using 1997-2011 national…
Abstract Number: 2808 • 2013 ACR/ARHP Annual Meeting
Favorable Outcome Of Hepatitis E Virus Infection In Patients With Inflammatory Arthritides Treated With Immunosupressants
Hélène Bauer¹, Cécile Luxembourger², Sophie Fournier³, Alain G. Cantagrel⁴, Jean Marie Peron³, Anne Marie Roque Afonso⁵, Pascal Claudepierre⁶, S. Fabre⁷, Christophe Hudry⁸, Guillaume Lefevre⁹, Antoine Martin¹⁰, Laurent Messer¹¹, Béatrice Pallot Prades¹², Christian Roux¹³, Christelle Sordet¹⁴, Claire Veissier¹⁵, Daniel Wendling¹⁶, Jacques-Eric Gottenberg¹⁷ and Jean Sibilia¹⁸, ¹rhumatologie, CHU de Hautepierre, Strasbourg, France, ²rhumatologie, CHU de Toulouse, Toulouse, France, ³Hépato-gastro-entérologie, CHU de Toulouse, Toulouse, France, ⁴Centre Hospitalier Universitaire de Toulouse, Toulouse, France, ⁵INSERM U785, CNR hépatites A et E, virologie hôpital Paul Brousse, Villejuif, France, ⁶Rheumatology, Henri Mondor Teaching Hospital, AP-HP, Créteil, France, ⁷Unité clinique d'immuno-rhumatologie, CHU MONTPELLIER, Montpellier, France, ⁸Rheumatology, Hopital Cochin, Paris, France, ⁹Lille University Hospital, Internal Medicine Department, Lille, France, ¹⁰Rhumatologie, Centre Hospitalier De St Brieuc, St Brieuc, France, ¹¹Rhumatologie, Hopitaux Civils de Colmar, Colmar, France, ¹²Rhumatologie, CHU St Etienne, St Etienne, France, ¹³Rheuamtology, CHU L' Archet University Nice, Nice, France, ¹⁴Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹⁵rhumatologie, CHU de Bordeaux, Bordeaux, France, ¹⁶Rheumatology, University Hospital, Besancon, France, ¹⁷Strasbourg University Hospital, Strasbourg, France, ¹⁸Rheumatology, CHU Hautepierre, Strasbourg, France
Background/Purpose: In inflammatory rheumatic diseases, the prevalence, clinical presentation and outcome of hepatitis E, an ubiquitous viral infection, remain unknown. We therefore addressed these issues…
Abstract Number: 2094 • 2012 ACR/ARHP Annual Meeting
Reactivation of Hepatitis B Virus in Autoimmune Disease Patients Receiving Immunosuppressive Agents
Daisuke Kobayashi¹, Satoshi Ito¹, Megumi Unno¹, Ichiei Narita² and Akira Murasawa¹, ¹Niigata Rheumatic Center, Niigata, Japan, ²Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
Background/Purpose: Reactivation of resolved hepatitis B in patients undergoing immunosuppressive therapy is now considered to be a complication of major clinical importance. Because this is…
Abstract Number: 1627 • 2012 ACR/ARHP Annual Meeting
New Insights Into the Presentation and the Management of Hepatitis B Reactivation in Patients with Autoimmune Diseases and Inflammatory Arthritis
Nina Droz¹, Laurent Gilardin², Patrice Cacoub Sr.³, Francis Berenbaum⁴, Daniel Wendling⁵, Bertrand Godeau⁶, Anne-Marie Piette⁷, Emmanuelle Dernis⁸, Mikael Ebbo⁹, Bruno Fautrel¹⁰, Arsène Meikinian¹¹, Aude Rigolet¹², Sophie Rivière¹³, Stanislas Pol¹⁴, Loic Guillevin¹⁵, Luc Mouthon¹⁶ and Benjamin Terrier¹⁷, ¹Internal Medicine, Cochin Hospital, Paris, France, ²Internal Medicine, Saint Antoine Hospital, Paris, France, ³Department of Internal Medicine 2., CHU Pitié-Salpêtrière, Paris, France, ⁴Rheumatology, AP-HP, St Antoine Hospital, Paris, France, ⁵Service de Rhumatologie, Minjoz University Hospital, Besancon, France, ⁶Internal Medicine, University of Paris, AP-HP, Hôpital Mondor Créteil, Creteil, France, ⁷Internal Medicine, Foch Hospital, Suresnes, France, ⁸Centre Hospitalier, Le Mans, France, ⁹Internal Medicine, Conception Hospital, Marseille, France, ¹⁰Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ¹¹Internal Medicine, Jean Verdier Hospital, Bondy, France, ¹²Internal Medicine I & II, Pitie-Salpetriere Hospital, APHP, UPMC Paris VI, Paris, France, ¹³Internal Medicine, Lapeyronie, Montpellier, France, ¹⁴Hepatology, Cochin Hospital, Paris, France, ¹⁵Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ¹⁶Internal Medicine, Hopital Cochin, Paris, France, ¹⁷Internal Medicine, Cochin University Hospital, Paris, France
Background/Purpose: In patients with autoimmune diseases and inflammatory arthritis, immunosuppressive therapy may trigger Hepatitis B virus (HBV) reactivation, leading to significant morbidity and mortality. Objective.…
Abstract Number: 354 • 2012 ACR/ARHP Annual Meeting
Delayed Onset of Hepatitis and/or Neutropenia in Patients with Rheumatoid Arthritis Treated with Combination Therapy of Methotrexate and Leflunomide
Seung Won Choi¹, Ji Seon Oh¹, You Jae Kim², Bon San Koo², Min Wook So², Yong-Gil Kim², Chang-Keun Lee² and Bin Yoo², ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, South Korea, ²Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
Background/Purpose: The adverse effects of combination therapy of methotrexate (MTX) and leflunomide (LEF) have been reported in many studies. Because combination of various doses of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].